This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rockwell Medical Reports Record Second Quarter Results

- Revenues Increase 19.2 %; Gross Profit Increases 49% -

- Conference Call at 8:30am ET to Discuss Results and Review Clinical Development -

WIXOM, Mich., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported second quarter 2010 results today.

Second Quarter Financial Highlights
  • Sales increased to $15.5 million, up 19.2% compared to the second quarter of 2009.
  • Gross profit increased to $2.8 million, up 49% or $0.9 million compared to the second quarter of 2009.
  • Gross profit margins increased to 17.9%, compared to 14.3% in the second quarter of 2009.
  • R&D expense was $0.4 million, compared to $2.0 million in the second quarter of 2009.
  • Net income was $.01 per share, compared to a loss of ($.12) per share in the second quarter of 2009.
  • Net income was $0.1 million, compared to a loss of ($1.7) million in the second quarter of 2009.

First Half 2010 Financial Highlights
  • Sales increased to $30.5 million, up 18.1% compared to the first half of 2009.
  • Gross profit increased to $5.1 million, up 67% or $2 million compared to the first half of 2009.
  • Gross profit margins increased to 16.7%, compared to 11.8% in the first half of 2009.
  • R&D expense was $1.0 million, compared to $3.3 million in the first half of 2009.
  • Net loss was ($.02) per share, compared to a loss of ($.25) per share in the first half of 2009.
  • Net loss was ($0.3) million, compared to a loss of ($3.4) million in the first half of 2009.
  • Cash and cash equivalents were $24.2 million at June 30, 2010, an increase of $1.2 million from December 31, 2009.

Second Quarter Drug Development and Corporate Progress
  • Successfully completed End of Phase II meeting with the FDA; confirmed approvable Phase III primary endpoint.
  • Presented SFP Phase IIb study data at European Dialysis Conference.
  • Appointed Dr. Ajay Singh to Scientific Advisory Board.

"We are pleased with our strong second quarter earnings, reflecting our best quarterly results to date. Our performance was in line with our expectations and we expect that our operating business will continue to generate cash to support the funding of our Phase III clinical development," stated Mr. Robert L. Chioini, Chairman and CEO of Rockwell. "From our recent End of Phase II meeting with the FDA, we confirmed a change in hemoglobin as an approvable primary efficacy endpoint for our Phase III study design. We intend to use a primary efficacy endpoint in the Phase III study that is identical to a secondary efficacy endpoint we had in our Phase IIb study, which achieved a statistically significant p-value, demonstrating an excess of 0.5 g/dL difference in hemoglobin between placebo and the SFP 10 ug/dl dose group." Mr. Chioini further stated, "Our regulatory path for SFP is now clear and we expect to submit our Phase III protocol design to the FDA shortly. We remain on track to start the pivotal Phase III program later this year." 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
RMTI $16.12 0.44%
AAPL $125.42 0.72%
FB $85.76 -0.04%
GOOG $520.51 -0.19%
TSLA $268.26 2.38%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs